Advertisement

Correction to: Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis

  • Sue Ping Thang
  • Mei Sim Lung
  • Grace Kong
  • Michael S. Hofman
  • Jason Callahan
  • Michael Michael
  • Rodney J. Hicks
Correction
  • 875 Downloads

Correction to: European Journal of Nuclear Medicine and Molecular Imaging

 https://doi.org/10.1007/s00259-017-3821-2

On page 4 of the original version of this article, the text "Eight (29%) of the patients had significant FDG-avid disease (i.e. with intensity above liver parenchyma) prior to treatment" needs to be corrected to "Eighty-nine percent of the patients had significant FDG-avid disease (i.e. with intensity above liver parenchyma) prior to treatment".

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  • Sue Ping Thang
    • 1
    • 3
  • Mei Sim Lung
    • 2
  • Grace Kong
    • 1
  • Michael S. Hofman
    • 1
  • Jason Callahan
    • 1
  • Michael Michael
    • 2
  • Rodney J. Hicks
    • 1
  1. 1.Centre for Cancer Imaging, Peter MacCallum Cancer CentreMelbourneAustralia
  2. 2.Division of Cancer Medicine, Neuroendocrine Tumour Unit, Peter MacCallum Cancer CentreMelbourneAustralia
  3. 3.Department of Nuclear Medicine and PETSingapore General HospitalSingaporeSingapore

Personalised recommendations